Suppression Of Recurrent Herpes Simplex Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for suppression of recurrent herpes simplex infection. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
3
Active US patents
79/100
Avg vulnerability
—
Annual revenue covered

Originators in Suppression Of Recurrent Herpes Simplex Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ligand Pharms 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating suppression of recurrent herpes simplex infection. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zovirax
ACYCLOVIR
 Ligand Pharms 3 79 — 2027-03-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8791127 Zovirax method of use 85 2027-03-23
8747896 Zovirax method of use 80 2027-06-03
8592434 Zovirax method of use 73 2030-06-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8592434 Zovirax method of use 73 2030-06-16
8747896 Zovirax method of use 80 2027-06-03
8791127 Zovirax method of use 85 2027-03-23

Related